Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation.

Fahey JL, Aziz N, Spritzler J, Plaeger S, Nishanian P, Lathey JL, Seigel J, Landay AL, Kilarui R, Schmitz JL, White C, Wara DW, Akridge R, Cutili J, Douglas SD, Reuben J, Shearer WT, Nokta M, Polland R, Schooley R, Asthana D, Mizrachi Y, Waxdal M.

Clin Diagn Lab Immunol. 2000 Jul;7(4):540-8.

2.

Distinct categories of immunologic changes in frail elderly.

Fahey JL, Schnelle JF, Boscardin J, Thomas JK, Gorre ME, Aziz N, Sadeghi H, Nishanian P.

Mech Ageing Dev. 2000 May 18;115(1-2):1-20.

PMID:
10854626
3.

Phenotypic and functional characteristics of circulating monocytes of elderly persons.

Sadeghi HM, Schnelle JF, Thoma JK, Nishanian P, Fahey JL.

Exp Gerontol. 1999 Dec;34(8):959-70.

PMID:
10673149
4.

The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes.

Plaeger S, Bass HZ, Nishanian P, Thomas J, Aziz N, Detels R, King J, Cumberland W, Kemeny M, Fahey JL.

Clin Immunol. 1999 Feb;90(2):238-46.

PMID:
10080836
5.

Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection.

Aziz N, Nishanian P, Taylor JM, Mitsuyasu RT, Jacobson JM, Dezube BJ, Lederman MM, Detels R, Fahey JL.

J Infect Dis. 1999 Apr;179(4):843-8.

PMID:
10068579
6.

Variables that affect assays for plasma cytokines and soluble activation markers.

Aziz N, Nishanian P, Mitsuyasu R, Detels R, Fahey JL.

Clin Diagn Lab Immunol. 1999 Jan;6(1):89-95.

7.
8.

Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements.

Fahey JL, Taylor JM, Manna B, Nishanian P, Aziz N, Giorgi JV, Detels R.

AIDS. 1998 Sep 10;12(13):1581-90.

PMID:
9764776
9.

Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection.

Salazar-Gonzalez JF, Martinez-Maza O, Nishanian P, Aziz N, Shen LP, Grosser S, Taylor J, Detels R, Fahey JL.

J Infect Dis. 1998 Aug;178(2):423-30.

PMID:
9697722
10.

Oral fluids as an alternative to serum for measurement of markers of immune activation.

Nishanian P, Aziz N, Chung J, Detels R, Fahey JL.

Clin Diagn Lab Immunol. 1998 Jul;5(4):507-12.

11.

Accelerated changes (inflection points) in levels of serum immune activation markers and CD4+ and CD8+ T cells prior to AIDS onset.

Nishanian P, Taylor JM, Manna B, Aziz N, Grosser S, Giorgi JV, Detels R, Fahey JL.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jun 1;18(2):162-70.

PMID:
9637581
12.

Cytokine gene expression in normal human lymphocytes in response to stimulation.

Fan J, Nishanian P, Breen EC, McDonald M, Fahey JL.

Clin Diagn Lab Immunol. 1998 May;5(3):335-40.

13.

Relation of impaired lymphocyte proliferative function to other major human immunodeficiency virus type 1-induced immunological changes.

Bass HZ, Fahey JL, Nishanian P, Detels R, Cumberland W, Kemeny M, Plaeger S.

Clin Diagn Lab Immunol. 1997 Jan;4(1):64-9.

14.

HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression.

Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J.

J Immunol. 1996 Sep 1;157(5):2168-73.

PMID:
8757343
15.

Induction of IL-6 and IL-10 production by recombinant HIV-1 envelope glycoprotein 41 (gp41) in the THP-1 human monocytic cell line.

Takeshita S, Breen EC, Ivashchenko M, Nishanian PG, Kishimoto T, Vredevoe DL, Martinez-Maza O.

Cell Immunol. 1995 Oct 15;165(2):234-42.

PMID:
7553888
16.

Characterization of immune suppression by a synthetic HIV gp41 peptide.

Wang H, Nishanian P, Fahey JL.

Cell Immunol. 1995 Apr 1;161(2):236-43.

PMID:
7697734
17.

HIV Gag p17 protein impairs proliferation of normal lymphocytes in vitro.

Hofmann B, Nishanian P, Fan J, Nguyen T, Fahey JL.

AIDS. 1994 Jul;8(7):1016-7. No abstract available.

PMID:
7946090
18.

Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes.

Hofmann B, Nishanian P, Nguyen T, Insixiengmay P, Fahey JL.

Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6676-80.

19.

Restoration of T-cell function in HIV infection by reduction of intracellular cAMP levels with adenosine analogues.

Hofmann B, Nishanian P, Nguyen T, Liu M, Fahey JL.

AIDS. 1993 May;7(5):659-64.

PMID:
8391271
20.

Immune changes in HIV-1 infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens.

Bass HZ, Nishanian P, Hardy WD, Mitsuyasu RT, Esmail E, Cumberland W, Fahey JL.

Clin Immunol Immunopathol. 1992 Jul;64(1):63-70.

PMID:
1376654
22.

Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1.

Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, Ho HN, Nishanian PG, Berzofsky JA, Shearer GM.

J Infect Dis. 1992 Jun;165(6):1012-9.

PMID:
1533867
23.

Acute lymphoid changes and ongoing immune activation in SIV infection.

Popov J, McGraw T, Hofmann B, Vowels B, Shum A, Nishanian P, Fahey JL.

J Acquir Immune Defic Syndr. 1992;5(4):391-9.

PMID:
1548574
24.

Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV infection: distinctive parameters of HIV-induced change.

Hofmann B, Nishanian P, Fahey JL, Esmail I, Jackson AL, Detels R, Cumberland W.

Clin Immunol Immunopathol. 1991 Nov;61(2 Pt 1):212-24.

PMID:
1680589
25.

Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease.

Nishanian P, Hofmann B, Wang Y, Jackson AL, Detels R, Fahey JL.

AIDS. 1991 Jul;5(7):805-12.

PMID:
1909873
26.

HIV inhibits the early steps of lymphocyte activation, including initiation of inositol phospholipid metabolism.

Hofmann B, Nishanian P, Baldwin RL, Insixiengmay P, Nel A, Fahey JL.

J Immunol. 1990 Dec 1;145(11):3699-705.

PMID:
1978848
27.
28.

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV.

N Engl J Med. 1990 Jan 18;322(3):166-72.

29.

Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression.

Ojo-Amaize E, Nishanian PG, Heitjan DF, Rezai A, Esmail I, Korns E, Detels R, Fahey J, Giorgi JV.

J Clin Immunol. 1989 Nov;9(6):454-61.

PMID:
2576558
30.

Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods.

Imagawa DT, Lee MH, Wolinsky SM, Sano K, Morales F, Kwok S, Sninsky JJ, Nishanian PG, Giorgi J, Fahey JL, et al.

N Engl J Med. 1989 Jun 1;320(22):1458-62.

PMID:
2716797
31.

Induction of IL-6 (B cell stimulatory factor-2/IFN-beta 2) production by HIV.

Nakajima K, Martínez-Maza O, Hirano T, Breen EC, Nishanian PG, Salazar-Gonzalez JF, Fahey JL, Kishimoto T.

J Immunol. 1989 Jan 15;142(2):531-6.

PMID:
2783441
33.

A simple and rapid method for preparation of HIV-expressing targets for functional assays.

Nishanian PG, Ojo-Amaize E, Uittenbogaart CH, Giorgi JV.

J Immunol Methods. 1988 Mar 16;107(2):261-71.

PMID:
3162252
34.

Analysis of false positive HIV-1 serologic testing in Kenya.

Kuhls TL, Nishanian PG, Cherry JD, Shen JP, Neumann CG, Stiehm ER, Ettenger RB, Bwibo NO, Koech D.

Diagn Microbiol Infect Dis. 1988 Mar;9(3):179-85.

PMID:
2840237
35.

Patterns of CD4+ cell changes after HIV-1 infection indicate the existence of a codeterminant of AIDS.

Detels R, English PA, Giorgi JV, Visscher BR, Fahey JL, Taylor JM, Dudley JP, Nishanian P, Muñoz A, Phair JP, et al.

J Acquir Immune Defic Syndr. 1988;1(4):390-5.

PMID:
2905742
36.

Antibody that inhibits human immunodeficiency virus reverse transcriptase and association with inability to isolate virus.

Sano K, Lee MH, Morales F, Nishanian P, Fahey J, Detels R, Imagawa DT.

J Clin Microbiol. 1987 Dec;25(12):2415-7.

37.

Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells.

Ojo-Amaize EA, Nishanian P, Keith DE Jr, Houghton RL, Heitjan DF, Fahey JL, Giorgi JV.

J Immunol. 1987 Oct 1;139(7):2458-63.

PMID:
2821115
38.

Detection of early antibodies in human immunodeficiency virus infection by enzyme-linked immunosorbent assay, Western blot, and radioimmunoprecipitation.

Saah AJ, Farzadegan H, Fox R, Nishanian P, Rinaldo CR Jr, Phair JP, Fahey JL, Lee TH, Polk BF.

J Clin Microbiol. 1987 Sep;25(9):1605-10.

39.

Selective alterations in immunoregulatory lymphocyte subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy-associated virus) infection.

Giorgi JV, Nishanian PG, Schmid I, Hultin LE, Cheng HL, Detels R.

J Clin Immunol. 1987 Mar;7(2):140-50.

PMID:
2883197
41.

Diagnostic and prognostic factors in AIDS.

Fahey JL, Taylor JM, Korns E, Nishanian P.

Mt Sinai J Med. 1986 Dec;53(8):657-63. No abstract available.

PMID:
3027546
43.

Leukemia derived growth factors produced by human malignant T-lymphoid cell lines.

Uittenbogaart CH, Nishanian PG, Anisman DJ, Erikson TK, Fahey JL.

Cancer Res. 1986 Mar;46(3):1219-23.

44.

Immunological changes in lymphadenopathy virus positive and negative symptomless male homosexuals: two years of observation.

Schwartz K, Visscher BR, Detels R, Taylor J, Nishanian P, Fahey JL.

Lancet. 1985 Oct 12;2(8459):831-2. No abstract available.

PMID:
2864550

Supplemental Content

Loading ...
Support Center